These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37362503)

  • 1. Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia.
    Fujino K; Ureshino H; Yoshida T; Ichinohe T
    Cureus; 2023 May; 15(5):e39481. PubMed ID: 37362503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 3. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 5. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
    Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
    Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
    Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
    Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y
    Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
    Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
    Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with
    Daido Y; Sugiura H; Ishikawa T; Kuroi T; Okamoto S; Nomura N; Masunari T; Sezaki N; Nannya Y; Ogawa S; Tanimoto M
    Case Rep Oncol; 2023; 16(1):999-1006. PubMed ID: 37900854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
    Kunisada K; Matsuoka A; Yoshida S; Taoka T
    Rinsho Ketsueki; 2022; 63(12):1621-1625. PubMed ID: 36653133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine.
    Zhang A; Johnson T; Abbott D; Phupitakphol T; Gutman JA; Pollyea DA; Koullias Y
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac486. PubMed ID: 36225746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.
    Zhao J; Wu S; Wang D; Edwards H; Thibodeau J; Kim S; Stemmer P; Wang G; Jin J; Savasan S; Taub JW; Ge Y
    Biochem Pharmacol; 2024 Oct; 228():116065. PubMed ID: 38373594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.
    Garciaz S; Hospital MA; Alary AS; Saillard C; Hicheri Y; Mohty B; Rey J; D'Incan E; Charbonnier A; Villetard F; Maisano V; Lombardi L; Ittel A; Mozziconacci MJ; Gelsi-Boyer V; Vey N
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
    Winters AC; Bosma G; Abbott D; Minhajuddin M; Jordan C; Pollyea DA; Gutman JA
    Transplant Cell Ther; 2022 Oct; 28(10):694.e1-694.e9. PubMed ID: 35902048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.
    Waclawiczek A; Leppä AM; Renders S; Stumpf K; Reyneri C; Betz B; Janssen M; Shahswar R; Donato E; Karpova D; Thiel V; Unglaub JM; Grabowski S; Gryzik S; Vierbaum L; Schlenk RF; Röllig C; Hundemer M; Pabst C; Heuser M; Raffel S; Müller-Tidow C; Sauer T; Trumpp A
    Cancer Discov; 2023 Jun; 13(6):1408-1427. PubMed ID: 36892565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
    Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR
    Front Oncol; 2022; 12():858202. PubMed ID: 35433414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
    Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
    Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
    Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax.
    Ehsan H; Iqbal Q; Masood A; Grunwald MR
    Leuk Res Rep; 2022; 18():100345. PubMed ID: 36051639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.
    Zhang LS; Wang J; Xu MZ; Wu TM; Huang SM; Cao HY; Sun AN; Liu SB; Xue SL
    Onco Targets Ther; 2022; 15():159-164. PubMed ID: 35221695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.